Cytochrome P450 2C9 2 and 3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type II Diabetes Mellitus

Sulfonylurea hypoglycemics are mainly metabolized by the cytochrome P450 2C9 (CYP2C9) enzyme. The CYP2C9*2 and *3 polymorphisms encode proteins with less enzymatic activity and are correlated with elevated serum levels of sulfonylurea, as demonstrated in healthy volunteers. In this study, the effect...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical pharmacology and therapeutics 2008-02, Vol.83 (2), p.288-292
Hauptverfasser:	Becker, ML, Visser, LE, Trienekens, PH, Hofman, A, Schaik, RHN, Stricker, BHCh
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aryl Hydrocarbon Hydroxylases - genetics Aryl Hydrocarbon Hydroxylases - metabolism Biological and medical sciences Blood Glucose - drug effects Cytochrome P-450 CYP2C9 Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - enzymology Diabetes Mellitus, Type 2 - genetics Diabetes. Impaired glucose tolerance Dose-Response Relationship, Drug Drug Prescriptions Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female Follow-Up Studies Gene Frequency Genotype Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacokinetics Male Medical sciences Middle Aged Pharmacology. Drug treatments Phenotype Polymorphism, Genetic Population Surveillance Prospective Studies Sulfonylurea Compounds - administration & dosage Sulfonylurea Compounds - pharmacokinetics Time Factors Tolbutamide - pharmacokinetics Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!